HomeMarket NewsMedtronic's Limited US Launch of Competing Product Could Impact AtriCure Shares

Medtronic’s Limited US Launch of Competing Product Could Impact AtriCure Shares

Actionable Trade Ideas

always free

Stock market background concept design of Bull and Bear with global network

FeelPic

After Medtronic’s limited US launch of a competing product to AtriCure’s AtriClip, Needham has maintained its buy rating on AtriCure (NASDAQ:ATRC). Despite Medtronic’s (NYSE:MDT) Penditure Left Atrial Appendage Exclusion System potentially piquing surgeon interest, AtriCure’s AtriClip, with over 400,000 units sold to date, boasts a long and successful track record, available in multiple versions. Needham noted penetration of only around 50% in the market.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.